BRD2 and cancer: Remarkable progress has recently been made in the detection of bacteria and their use in predicting the efficacy of immunotherapy in cancer patients.[13] In this retrospective analysis, we performed a systematic series of experiments to delineate a microbiota‐based risk prediction (MRP) model, including Prevotella, Sphingobacterium, and TM7x, to complement the existing system for predicting the treatment efficiency of NAT and the prognosis of patients with ESCC.